{
    "root": "315730ec-c40c-af1a-e063-6294a90a010f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Eltrombopag",
    "value": "20250327",
    "ingredients": [
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32159"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "ELTROMBOPAG OLAMINE",
            "code": "4U07F515LG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85010"
        }
    ],
    "indications": {
        "text": "eltrombopag oral suspension thrombopoietin receptor agonist indicated : \u2022 treatment thrombocytopenia adult pediatric patients 1 year older persistent chronic immune thrombocytopenia ( itp ) insufficient response corticosteroids , immunoglobulins , splenectomy . eltrombopag oral suspension used patients itp whose degree thrombocytopenia condition increase risk bleeding . ( 1.1 ) \u2022 treatment thrombocytopenia patients chronic hepatitis c allow initiation maintenance interferon-based therapy . eltrombopag oral suspension used patients chronic hepatitis c whose degree thrombocytopenia prevents initiation interferon-based therapy limits ability maintain interferon-based therapy . ( 1.2 ) \u2022 treatment patients severe aplastic anemia insufficient response immunosuppressive therapy . ( 1.3 ) limitations : \u2022 eltrombopag oral suspension indicated treatment patients myelodysplastic syndrome ( mds ) . ( 1.4 ) \u2022 safety efficacy established combination direct-acting antiviral agents used without interferon treatment chronic hepatitis c infection . ( 1.4 )",
        "doid_entities": [
            {
                "text": "thrombocytopenia (DOID:1588)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1588"
            },
            {
                "text": "immune thrombocytopenia (DOID:1587)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1587"
            },
            {
                "text": "chronic hepatitis (DOID:2237)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2237"
            },
            {
                "text": "chronic hepatitis c (DOID:1883)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1883"
            },
            {
                "text": "aplastic anemia (DOID:12449)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12449"
            },
            {
                "text": "anemia (DOID:2355)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2355"
            },
            {
                "text": "myelodysplastic syndrome (DOID:0050908)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050908"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "mds (DOID:0060469)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060469"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe aplastic anemia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_182040"
            },
            {
                "disease": "chronic hepatitis c",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_98255"
            },
            {
                "disease": "chronic immune thrombocytopenia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_3002"
            }
        ]
    },
    "contraindications": {
        "text": "take eltrombopag oral suspension without meal meal low calcium ( \u2264 50 mg ) . take eltrombopag oral suspension least 2 hours 4 hours medications products containing polyvalent cations , antacids , calcium-rich foods , mineral supplements . ( 2.4 , 7.1 , 12.3 ) persistent chronic itp : initiate eltrombopag oral suspension 50 mg daily adult pediatric patients 6 years older , 25 mg daily pediatric patients aged 1 5 years . dose reductions needed patients hepatic impairment patients east-/southeast-asian ancestry . adjust maintain platelet count greater equal 50 x 10 9 /l . exceed 75 mg per day . ( 2.1 , 8.6 , 8.7 ) chronic hepatitis c-associated thrombocytopenia : initiate eltrombopag oral suspension 25 mg daily patients . adjust achieve target platelet count required initiate antiviral therapy . exceed daily dose 100 mg. ( 2.2 ) refractory severe aplastic anemia : initiate eltrombopag oral suspension 50 mg daily . reduce initial dose patients hepatic impairment patients east-/southeast-asian ancestry . adjust maintain platelet count greater 50 x 10 9 /l . exceed 150 mg per day . ( 2.3 , 8.6 , 8.7 )",
        "doid_entities": [
            {
                "text": "chronic hepatitis (DOID:2237)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2237"
            },
            {
                "text": "thrombocytopenia (DOID:1588)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1588"
            },
            {
                "text": "aplastic anemia (DOID:12449)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12449"
            },
            {
                "text": "anemia (DOID:2355)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2355"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe aplastic anemia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_182040"
            },
            {
                "disease": "chronic hepatitis c",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_98255"
            }
        ]
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "Eltrombopag for oral suspension is a thrombopoietin receptor agonist indicated: \u2022\u00a0for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag for oral suspension should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) \u2022\u00a0for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag for oral suspension should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) \u2022\u00a0for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: \u2022\u00a0Eltrombopag for oral suspension is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) \u2022\u00a0Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 )",
    "contraindications_original": "Take eltrombopag for oral suspension without a meal or with a meal low in calcium (\u2264 50 mg). Take eltrombopag for oral suspension at least 2 hours before or 4 hours after any medications or products containing polyvalent cations, such as antacids, calcium-rich foods, and mineral supplements. ( 2.4 , 7.1 , 12.3 ) Persistent or Chronic ITP: Initiate eltrombopag for oral suspension at 50 mg once daily for most adult and pediatric patients 6 years and older, and at 25 mg once daily for pediatric patients aged 1 to 5 years. Dose reductions are needed for patients with hepatic impairment and some patients of East-/Southeast-Asian ancestry. Adjust to maintain platelet count greater than or equal to 50 x 10 9 /L. Do not exceed 75 mg per day. ( 2.1 , 8.6 , 8.7 ) Chronic Hepatitis C-associated Thrombocytopenia: Initiate eltrombopag for oral suspension at 25 mg once daily for all patients. Adjust to achieve target platelet count required to initiate antiviral therapy. Do not exceed a daily dose of 100 mg. ( 2.2 ) Refractory Severe Aplastic Anemia: Initiate eltrombopag for oral suspension at 50 mg once daily. Reduce initial dose in patients with hepatic impairment or patients of East-/Southeast-Asian ancestry. Adjust to maintain platelet count greater than 50 x 10 9 /L. Do not exceed 150 mg per day. ( 2.3 , 8.6 , 8.7 )",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Eltrombopag",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85010"
        }
    ]
}